<DOC>
	<DOCNO>NCT01394354</DOCNO>
	<brief_summary>Primary objective study determination maximum tolerate dose ( MTD ) Vorinostat ( V ) , give combination fix dos Doxorubicin ( D ) , Bortezomib ( B ) Dexamethasone ( D ) . Secondary objective : Assessment safety tolerability VBDD ; efficacy data VBDD .</brief_summary>
	<brief_title>Vorinostat Combination With Bortezomib , Doxorubicin Dexamethasone ( VBDD ) Patients With Refractory Relapsed Multiple Myeloma ( MM )</brief_title>
	<detailed_description>A first cohort three patient treat start dose level Vorinostat 100 mg/d , day 1-4 , 8-11 , 15-18 combination BDD . The dose level Vorinostat escalate new cohort : dose limit toxicity ( DLT ) observe previous dose level 3 patient , second cohort 3 new patient treat Vorinostat 200 mg/d third cohort give Vorinostat 300 mg/d . Bortezomib administer intravenously ( i.v . ) 1.3mg/m2 d1 , 8 , 15 . Doxorubicin administer i.v . total dose 18 mg/m2 per cycle ( 9 mg/m2 , d1 8 ) . Dexamethasone administer per o ( p.o . ) 40mg ( first cycle ) 20mg ( subsequent cycle ) d1 , 8 , 15 , 22 .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Patients refractory relapse MM least firstline chemotherapy ( CTx ) PBSCT ( autologous allogeneic SCT ) . All line relapse eligible . KPS ≥60 % Adequate BM function Adequate hepatic renal function ( AST ALT ≤2.5 time ULN , Bilirubin ≤1.5 time ULN , eGFR &gt; 20 ml/min ) Patient prior treatment Vorinostat HDAC inhibitor Patients severe hepatic impairment acute diffuse infiltrative pulmonary pericardial disease Patient preexist NCI CTC ≥grade 3 neuropathy Patient know CNS MMinvolvement and/or MMrelated/induced meningitis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Multiple Myeloma relapse refractory</keyword>
</DOC>